Inactive Instrument

Company ImmunoGen, Inc.




Biotechnology & Medical Research

Business Summary

ImmunoGen, Inc. is a commercial-stage biotechnology company. The Company is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The Company is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).

Number of employees: 277


Managers TitleAgeSince
Director of Finance/CFO 45 23-09-17
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 61 23-01-03
Investor Relations Contact - -
Corporate Officer/Principal 53 23-04-23
Comptroller/Controller/Auditor 46 03-12-31
Corporate Officer/Principal 53 20-06-02
General Counsel - 08-12-31
Human Resources Officer - 13-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 279,354,016 279,140,089 ( 99.92 %) 0 99.92 %

Company contact information

ImmunoGen, Inc.

830 Winter Street

02451-1477, Waltham

+781 895 0600
address ImmunoGen, Inc.(IMGN)
  1. Stock Market
  2. Equities
  3. IMGN Stock
  4. Company ImmunoGen, Inc.